Leading Multi-Specialty Hospital Chain with Strong Growth Prospects, but Premium Valuation Limits Upside

• Manipal Health Enterprises Ltd. is one of India's largest private multi-specialty hospital chains, operating 49 hospitals with over 13,000 licensed beds across key metropolitan and Tier-I cities. The company has built a strong brand in tertiary and quaternary healthcare with a diversified presence across oncology, cardiology, organ transplantation, neurosciences and critical care.
• The company has demonstrated robust financial growth, supported by higher occupancy levels, improving average revenue per occupied bed (ARPOB), acquisitions and operational efficiencies. India's healthcare sector continues to benefit from rising insurance penetration, increasing lifestyle diseases, ageing demographics and growing demand for quality healthcare infrastructure, providing favourable long-term industry tailwinds.
• The IPO comprises a Fresh Issue of ₹8,000 crore and an Offer for Sale of ₹1,275.22 crore. A substantial portion of the fresh issue proceeds will be utilised towards debt reduction and funding recent acquisitions, strengthening the balance sheet and supporting future expansion.
• While Manipal Health possesses an attractive business model, strong market position and favourable long-term growth outlook, the IPO is priced at a premium valuation relative to earnings. Although the premium may be justified by the company's scale and quality, we believe the current valuation largely captures these strengths, limiting the near-term risk-reward.
• Recommendation: We assign a NEUTRAL view on the IPO. Manipal Health is a high-quality healthcare franchise with strong operating metrics, a diversified hospital network and favourable structural growth drivers. However, considering the premium valuation and the significant allocation of fresh issue proceeds towards balance-sheet optimisation and acquisition-related funding, we believe the current pricing offers a balanced risk-reward. Long-term investors may continue to monitor the company's execution, profitability and post-listing valuation before building meaningful exposure.